| Description of Property | Date Acquired | Cost or Other Basis | Prior Years' Depreciation | Computation Method | Rate / Life (# of years) |
Current Year's Depreciation Expense | Net Investment Income | Adjusted Net Income | Cost of Goods Sold Not Included |
|---|
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| A.C. MOORE ARTS & CRAFTS, INC | 325,834 | 316,423 |
| AKEBIA THERAPEUTICS, INC | 1,151,990 | 849,092 |
| ALBIREO PHARMA INC | 20,436 | 21,537 |
| ALIMERA SCIENCES INC | 147,310 | 118,398 |
| ALLENA PHARMACEUTICALS INC | 136,046 | 76,807 |
| ALPINE IMMUNE SCIENCES | 261,846 | 170,410 |
| APOLLO ENDOSURGERY | 173,838 | 125,425 |
| APTEVO THERAPEURTICS, INC | 328,730 | 100,324 |
| APTOSE BIOSCIENCE | 132,344 | 89,770 |
| AQUINOX PHARMACEUTICALS INC | 172,528 | 147,889 |
| AXCELIS TECHNOLOGIES INC | 202,754 | 183,340 |
| AXSOME THERAPEUTICS | 23,398 | 13,987 |
| AZURRX BIOPHARMA | 116,809 | 77,819 |
| CATABASIS PHARMACEUTICALS INC | 3,425 | 2,185 |
| CHEMBIO DIAGNOSTICS INC | 377,231 | 340,421 |
| COHU INC | 90,590 | 76,943 |
| CORVIS CORPORATION | 70,923 | 45,318 |
| EMCORE CORPORATION | 239,569 | 189,727 |
| EYENOVIA INC | 804 | 570 |
| FLEXSHOPPER INC | 3,832 | 3,442 |
| FOAMIX PHARMACEUTICALS LTD | 25,357 | 21,899 |
| KURA ONCOLOGY INC | 559,759 | 477,248 |
| LIFE TECHNOLOGIES CORP | 6,798 | 5,000 |
| LIPOCINE INC NEW COM | 61,366 | 39,000 |
| LIQTECH INTERNATIONAL INC | 39,016 | 40,415 |
| MOLECULAR TEMPLATES INC | 57,852 | 52,520 |
| MOTUS GI HOLDINGS ORD SHS | 94,822 | 108,629 |
| NEOS THERAPEUTICS INC | 167,665 | 130,368 |
| OPHTHOTECH CORP | 6,103 | 6,000 |
| OTONOMY INC | 9,941 | 8,099 |
| PACIFIC ETHANOL INC | 330,324 | 194,445 |
| POLARITYTE INC | 11,979 | 12,546 |
| RA MEDICAL SYSTEMS INC | 61,217 | 63,600 |
| RECRO PHARMA INC | 62,310 | 58,220 |
| RESONANT INC | 162,174 | 60,786 |
| ROCKET PHARMACEUTICALS INC | 61,549 | 65,356 |
| ROSETTA RESOURCES INC. | 357,713 | 130,678 |
| SCYNEXIS INC | 54,031 | 29,250 |
| SEQUANS COMMUNICATIONS SA | 195,144 | 145,374 |
| SIERRA ONCOLOGY | 118,263 | 87,263 |
| SOLENO THERAPEUTICS INC | 37,089 | 30,267 |
| STEMLINE THERAPEUTICS | 8,749 | 9,500 |
| STRONGBRIDGE BIOPHARMA PLC | 649,451 | 616,174 |
| SURFACE ONCOLOGY INC | 718 | 424 |
| TRACON PHARMACEUTICALS | 222,724 | 59,963 |
| VERTTEX ENERGY, INC | 186,893 | 155,867 |
| WESTPORT INNOVATIONS INC | 81,924 | 43,890 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Administrative Fees | 22,305 | 22,305 | ||
| Bank Charges | 38 | 37 | ||
| State or Local Filing Fees | 25 | 25 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| 990-PF Estimated Tax for 2018 | 9,000 | |||
| 990-PF Extension for 2017 | 1,189 | |||
| 990-T EXTENSION FOR 2017 | 1,712 | |||
| 990-T Income Tax for 2017 | 17 | |||
| Foreign Tax Paid | 45 | 44 |